Furthermore, an IGF1 receptor inhibitor can partially block the drug resistance actions of hPL, supporting the idea that platelet-associated IGF1 may modulate HCC resistance to multikinase inhibitor effects. Here, LGALS1 is linked to hepatocellular carcinoma.